Magle Chemsowed Holding AB (PUBL) – PUBLISHES FULL YEAR REPORT 2021
Magle Chemoswed Holding AB (publ), an established innovation led healthcare group with proven growth through risk diversification and focus on high-value revenue streams, today publishes the interim report for the fourth quarter 2021 and the full year 2021.
SOLID REVENUES WITH INCREASED RETURNS
OCTOBER – DECEMBER 2021
- Net sales amounted to 35.9 MSEK (35.6)
- EBITDA equalled 4.4 MSEK (2.7)
- Operating profit (EBIT) is 1.3 MSEK (0.1)
- Profit after tax amounted to 1.1 MSEK (-0.1)
- Earnings per share amounted to SEK 0.11 (-0.01) per share
JANUARY – DECEMBER 2021
- Net sales amounted to 132.2 MSEK (142.3) adjusted for revenue recognition change in 2021 net sales amounted to 139.3 (142.3)
- EBITDA equalled 16.9 MSEK (16.2)
- Operating profit (EBIT) is 5.3 MSEK (4.5)
- Profit after tax amounted to 4.4 MSEK (1.8)
- Earnings per share amounted to SEK 0.4 (0.2) per share
Justin Pierce, CEO of Magle Chemoswed Holding AB, commented, “I am proud of our many contributions that we have made in 2021, we remain on track strategically and the focus on profitability and return for 2021 has met our expectations and demonstrates the underlying stability of the business.”
EVENTS DURING THE REPORTING PERIOD
Martin Lidgard appointed to the Board of Directors
EVENTS AFTER THE REPORTING PERIOD
Simon Jegou joined as new Chief Strategy Officer
Ethical approval granted for the post market clinical study for SmartPan®.
The full report can be downloaded at https://maglegroup.com/financial-reports/
